SOD2 and glioblastoma: Therefore, AXT usage and effects should be carefully monitored, especially in GBM patients, since overall SOD2 expression in GBM tumors of patients is higher compared to nearby healthy tissue (Supplementary Figure S2A), and overall disease-free survival was lower in the high SOD2 expressing patient group with a hazard ratio of SOD2 close to 1.8 (Supplementary Figure S2B).